EGFR and non-small cell lung carcinoma: Furthermore, another study has suggested that in NSCLC patients with EGFR mutations (E19del/L858R) and high programmed death-ligand 1 (PD-L1) expression, the prognosis with EGFR-TKI treatment is less favorable than that with low PD-L1 expression [13].